Market Overview

UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential

Share:
Related GHDX
Mid-Morning Market Update: Markets Open Higher; Time Warner Posts Mixed Q4 Results
Benzinga's Top #PreMarket Losers
Genomic Health's (GHDX) CEO Kimberly Popovits Q4 2015 Results - Earnings Call Transcript (Seeking Alpha)

Credit Suisse initiated coverage on Genomic Health (NASDAQ: GHDX) with an Outperform rating and a $43 price target.

Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer."

Genomic Health closed at $36.15 on Monday.

Latest Ratings for GHDX

DateFirmActionFromTo
Jan 2016Piper JaffrayDowngradesOverweightNeutral
Jan 2016Canaccord GenuityUpgradesHoldBuy
Nov 2015UBSUpgradesNeutralBuy

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GHDX)

Get Benzinga's Newsletters